| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 1.42 Billion |
| Market Size (2030) | USD 2.19 Billion |
| CAGR (2025 - 2030) | 9.10 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Sodium-dependent Glucose Cotransporter 2 Market Analysis
The Europe Sodium-dependent Glucose Cotransporter 2 Market size is estimated at USD 1.42 billion in 2025, and is expected to reach USD 2.19 billion by 2030, at a CAGR of 9.1% during the forecast period (2025-2030).
The European region had witnessed an alarming increase in the prevalence of diabetes, in recent years. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as medications or ingestion of additional carbohydrates by monitoring their blood glucose levels.
The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. Non-insulin treatments, used as first-line therapies for patients with type 2 diabetes, currently capture more than half the sales in the anti-diabetic market. Over the past decade, two important classes entered this market: dipeptidyl peptidase-4 inhibitors (DPP-4) and sodium-glucose cotransporter-2 inhibitors (SGLT-2). These agents work in various ways to reduce blood sugar levels in people with type 2 diabetes. Some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Europe Sodium-dependent Glucose Cotransporter 2 Market Trends
Increasing diabetes prevalence
The diabetes population in the European region is expected to rise by more than 5% over the forecast period.
According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. These figures indicate that approximately 9% of the total healthcare expenditure is spent on diabetes in Europe. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.
SGLT-2 inhibitor drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required, along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. SGLT-2 inhibitor drugs help diabetes patients control their condition and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost, so they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.
The government and the companies are working towards better diabetes management. For instance, the National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. Such advantages helped in the market growth.
Understand The Key Trends Shaping This Market
Download PDF
Germany held the highest market share in the European Sodium-dependent Glucose Cotransporter 2 Market in the current year
Germany held the highest market share of about 28% in the European Sodium-dependent Glucose Cotransporter 2 Market in the current year.
Diabetes is a significant health problem and one of the extraordinary challenges for healthcare systems all over Germany. The prevalence of known type 1 & 2 diabetes in the German adult population is very high, along with many patients not yet diagnosed with the disease. Due to an aging population and unhealthy lifestyle, the prevalence of type 2 diabetes is expected to increase steadily over the next few years. High-quality care, including adequate monitoring, control of risk factors, and active self-management, are the key factors for preventing complications in German patients with type 2 diabetes.
According to the German Diabetes Centre (DDZ), about 8.5 million people in Germany are affected by diabetes. The number of people with type 2 diabetes in Germany will continue to increase over the next twenty years. German law requires public plans to cap out-of-pocket health care costs and to cover all medically necessary treatment, including insulin. Germany is one of the developed countries with advanced healthcare facilities.
Moreover, reimbursement and pricing policies are highly regulated, which drives the market. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some of the market opportunities for the players in the German market.
Get Analysis on Important Geographic Markets
Download PDF
Europe Sodium-dependent Glucose Cotransporter 2 Industry Overview
The European SGLT-2 market is consolidated, with a few significant global manufacturers: Janssen, Eli Lilly, AstraZeneca, and Bristol Myers Squibb. The joint ventures that occurred between players in the recent past helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance, a very popular SGLT-2 class drug.
Europe Sodium-dependent Glucose Cotransporter 2 Market Leaders
-
Bristol Myers Squibb
-
AstraZeneca
-
Boehringer Ingelheim
-
Janssen Pharmaceuticals
-
Eli Lilly and Company
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Europe Sodium-dependent Glucose Cotransporter 2 Market News
- February 2023: AstraZeneca's Forxiga (dapagliflozin) was approved in the European Union to extend the indication for heart failure with reduced ejection fraction. It is to cover patients across the full spectrum of left ventricular ejection fraction, including HF with mildly reduced and preserved ejection fraction.
- March 2022: Eli Lilly and Boehringer Ingelheim gained approval for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor, Jardiance (empagliflozin). Previously Jardiance gained a label expansion for treating heart failure in the US.
Europe Sodium-dependent Glucose Cotransporter 2 Industry Segmentation
SGLT-2 inhibitors are an oral medication for treating type 2 diabetes in adults. They are prescription drugs called sodium-glucose co-transporter-2 inhibitors (SLGT2i) or gliflozins. The Europe Sodium-dependent Glucose Cotransporter 2 Market is segmented into drugs and geography . The report offers the value (in USD) and volume (in units) for the above segments.
| Drugs | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | |
| Farxiga/Forxiga (Dapagliflozin) | |
| Geography | France |
| Germany | |
| Italy | |
| Spain | |
| United Kingdom | |
| Russia | |
| Rest of Europe |
Need A Different Region or Segment?
Customize Now
Europe Sodium-dependent Glucose Cotransporter 2 Market Research FAQs
How big is the Europe Sodium-dependent Glucose Cotransporter 2 Market?
The Europe Sodium-dependent Glucose Cotransporter 2 Market size is expected to reach USD 1.42 billion in 2025 and grow at a CAGR of 9.10% to reach USD 2.19 billion by 2030.
What is the current Europe Sodium-dependent Glucose Cotransporter 2 Market size?
In 2025, the Europe Sodium-dependent Glucose Cotransporter 2 Market size is expected to reach USD 1.42 billion.
Who are the key players in Europe Sodium-dependent Glucose Cotransporter 2 Market?
Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals and Eli Lilly and Company are the major companies operating in the Europe Sodium-dependent Glucose Cotransporter 2 Market.
What years does this Europe Sodium-dependent Glucose Cotransporter 2 Market cover, and what was the market size in 2024?
In 2024, the Europe Sodium-dependent Glucose Cotransporter 2 Market size was estimated at USD 1.29 billion. The report covers the Europe Sodium-dependent Glucose Cotransporter 2 Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Sodium-dependent Glucose Cotransporter 2 Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Europe Sodium-Glucose Cotransporter Industry Report
Statistics for the 2025 Europe Sodium-dependent Glucose Cotransporter 2 market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Europe Sodium-dependent Glucose Cotransporter 2 analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
